Search

Your search keyword '"Canzonieri, Vincenzo"' showing total 16 results
Start Over Author "Canzonieri, Vincenzo" Journal international journal of molecular sciences
16 results on '"Canzonieri, Vincenzo"'

3. Overview of Epstein–Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options

Author

De Re, Valli, primary, Brisotto, Giulia, additional, Repetto, Ombretta, additional, De Zorzi, Mariangela, additional, Caggiari, Laura, additional, Zanussi, Stefania, additional, Alessandrini, Lara, additional, Canzonieri, Vincenzo, additional, Miolo, Gianmaria, additional, Puglisi, Fabio, additional, Belluco, Claudio, additional, Steffan, Agostino, additional, and Cannizzaro, Renato, additional

Published
2020
Full Text
View/download PDF

9. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)

Author

Garziera, Marica, primary, Cecchin, Erika, additional, Canzonieri, Vincenzo, additional, Sorio, Roberto, additional, Giorda, Giorgio, additional, Scalone, Simona, additional, De Mattia, Elena, additional, Roncato, Rossana, additional, Gagno, Sara, additional, Poletto, Elena, additional, Romanato, Loredana, additional, Sartor, Franca, additional, Polesel, Jerry, additional, and Toffoli, Giuseppe, additional

Published
2018
Full Text
View/download PDF

11. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

Author

Caggiari, Laura, primary, Miolo, Gianmaria, additional, Buonadonna, Angela, additional, Basile, Debora, additional, Santeufemia, Davide, additional, Cossu, Antonio, additional, Palmieri, Giuseppe, additional, De Zorzi, Mariangela, additional, Fornasarig, Mara, additional, Alessandrini, Lara, additional, Canzonieri, Vincenzo, additional, Lo Re, Giovanni, additional, Puglisi, Fabio, additional, Steffan, Agostino, additional, Cannizzaro, Renato, additional, and De Re, Valli, additional

Published
2017
Full Text
View/download PDF

12. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients

Author

Dreussi, Eva, primary, Cecchin, Erika, additional, Polesel, Jerry, additional, Canzonieri, Vincenzo, additional, Agostini, Marco, additional, Boso, Caterina, additional, Belluco, Claudio, additional, Buonadonna, Angela, additional, Lonardi, Sara, additional, Bergamo, Francesca, additional, Gagno, Sara, additional, De Mattia, Elena, additional, Pucciarelli, Salvatore, additional, De Paoli, Antonino, additional, and Toffoli, Giuseppe, additional

Published
2016
Full Text
View/download PDF

13. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.

Author

Caggiari, Laura, Miolo, Gianmaria, Buonadonna, Angela, Basile, Debora, Santeufemia, Davide A., Cossu, Antonio, Palmieri, Giuseppe, De Zorzi, Mariangela, Fornasarig, Mara, Alessandrini, Lara, Canzonieri, Vincenzo, Lo Re, Giovanni, Puglisi, Fabio, Steffan, Agostino, Cannizzaro, Renato, and De Re, Valli

Subjects
STOMACH cancer, DISEASE susceptibility, CANCER invasiveness, CADHERINS, EPIDERMAL growth factor receptors, TRASTUZUMAB, GENETIC polymorphisms, THERAPEUTICS
Abstract

The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

14. Overview of Epstein–Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options.

Author

Re, Valli De, Brisotto, Giulia, Repetto, Ombretta, De Zorzi, Mariangela, Caggiari, Laura, Zanussi, Stefania, Alessandrini, Lara, Canzonieri, Vincenzo, Miolo, Gianmaria, Puglisi, Fabio, Belluco, Claudio, Steffan, Agostino, and Cannizzaro, Renato

Subjects
STOMACH cancer, EPSTEIN-Barr virus, PROGNOSIS, VIRUS identification, CLASSIFICATION, IMMUNE response
Abstract

Gastric cancer (GC) is a deadly disease with poor prognosis that is characterized by heterogeneity. New classifications based on histologic features, genotypes, and molecular phenotypes, for example, the Cancer Genome Atlas subtypes and those by the Asian Cancer Research Group, help understand the carcinogenic differences in GC and have led to the identification of an Epstein–Barr virus (EBV)-related GC subtype (EBVaGC), providing new indications for tailored treatment and prognostic factors. This article provides a review of the features of EBVaGC and an update on the latest insights from EBV-related research with a particular focus on the strict interaction between EBV infection and the gastric tumor environment, including the host immune response. This information may help increase our knowledge of EBVaGC pathogenesis and the mechanisms that sustain the immune response of patients since this mechanism has been demonstrated to offer a survival advantage in a proportion of patients with GC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

15. Proposed Molecular and miRNA Classification of Gastric Cancer

Author

Valli De Re, Melissa Manchi, Riccardo Dolcetti, Vincenzo Canzonieri, Lara Alessandrini, Alessandrini, Lara, Manchi, Melissa, De Re, Valli, Dolcetti, Riccardo, and Canzonieri, Vincenzo

Subjects
0301 basic medicine, Review, Gene mutation, EBV infection, Epigenesis, Genetic, lcsh:Chemistry, molecular gastric cancer subtype, 0302 clinical medicine, gene mutation, preclinical model, lcsh:QH301-705.5, Spectroscopy, Epigenesis, MicroRNA, General Medicine, preclinical models, Computer Science Applications, Gene Expression Regulation, Neoplastic, 030220 oncology & carcinogenesis, gene expression profile, Identification (biology), Microsatellite Instability, Human, Signal Transduction, microsatellite, Computational biology, Catalysis, Inorganic Chemistry, 03 medical and health sciences, Genetic, Stomach Neoplasm, Prognostic classification, Stomach Neoplasms, microRNA, medicine, Animals, Humans, gastric cancer, miRNA, MicroRNAs, Mutation, Transcriptome, Functional studies, Epigenetics, Physical and Theoretical Chemistry, Molecular Biology, Neoplastic, Animal, Organic Chemistry, Cancer, medicine.disease, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, Gene Expression Regulation
Abstract

Gastric cancer (GC) is a common malignant neoplasm worldwide and one of the main cause of cancer-related deaths. Despite some advances in therapies, long-term survival of patients with advanced disease remains poor. Different types of classification have been used to stratify patients with GC for shaping prognosis and treatment planning. Based on new knowledge of molecular pathways associated with different aspect of GC, new pathogenetic classifications for GC have been and continue to be proposed. These novel classifications create a new paradigm in the definition of cancer biology and allow the identification of relevant GC genomic subsets by using different techniques such as genomic screenings, functional studies and molecular or epigenetic characterization. An improved prognostic classification for GC is essential for the development of a proper therapy for a proper patient population. The aim of this review is to discuss the state-of-the-art on combining histological and molecular classifications of GC to give an overview of the emerging therapeutic possibilities connected to the latest discoveries regarding GC.

Published
2018

16. Quantitative Proteomic Approach Targeted to Fibrinogen β Chain in Tissue Gastric Carcinoma

Author

Valli De Re, Raffaella Magris, Renato Cannizzaro, Gianmaria Miolo, Agostino Steffan, Ombretta Repetto, Stefania Maiero, Maria Rita Cozzi, Vincenzo Canzonieri, Repetto, Ombretta, Maiero, Stefania, Magris, Raffaella, Miolo, Gianmaria, Cozzi, Maria, Steffan, Agostino, Canzonieri, Vincenzo, Cannizzaro, Renato, and De Re, Valli

Subjects
Male, Proteomics, 0301 basic medicine, Angiogenesis, comparative proteomic, Fibrinogen, Mass Spectrometry, lcsh:Chemistry, 0302 clinical medicine, Electrophoresis, Gel, Two-Dimensional, Platelet, fibrinogen β chain, Databases, Protein, FGB, lcsh:QH301-705.5, Spectroscopy, DIGE, platelet, Gel electrophoresis, Chemistry, General Medicine, Middle Aged, comparative proteomics, gastric cancer, coagulation, platelets, biomarker, Computer Science Applications, Coagulation, 030220 oncology & carcinogenesis, Female, medicine.symptom, Protein Binding, medicine.drug, Adult, Inflammation, Article, Catalysis, Inorganic Chemistry, 03 medical and health sciences, Stomach Neoplasms, medicine, Humans, Physical and Theoretical Chemistry, Molecular Biology, Aged, Carcinoma, Organic Chemistry, fibrinogen beta chain, Computational Biology, Reproducibility of Results, Cancer, medicine.disease, Molecular biology, Protein Subunits, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, Tumor progression, Carrier Proteins, Protein Processing, Post-Translational
Abstract

Elevated plasma fibrinogen levels and tumor progression in patients with gastric cancer (GC) have been largely reported. However, distinct fibrinogen chains and domains have different effects on coagulation, inflammation, and angiogenesis. The aim of this study was to characterize fibrinogen beta chain (FGB) in GC tissues. Retrospectively we analyzed the data of matched pairs of normal (N) and malignant tissues (T) of 28 consecutive patients with GC at diagnosis by combining one- and two-dimensional electrophoresis (1DE and 2DE) with immunoblotting and mass spectrometry together with two-dimensional difference in gel electrophoresis (2D-DIGE). 1DE showed bands of the intact FGB at 50 kDa and the cleaved forms containing the fragment D at similar to 37-40 kDa, which corresponded to 19 spots in 2DE. In particular, spot 402 at similar to 50 kDa and spots 526 and 548 at similar to 37 kDa were of interest by showing an increased expression in tumor tissues. A higher content of spot 402 was associated with stomach antrum, while spots 526 and 548 amounts correlated with corpus and high platelet count (>208 x 10(9)/L). The quantification of FGB and cleaved products may help to further characterize the interconnections between GC and platelet/coagulation pathways.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results